CRESCENT BIOPHARMA, INC. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent
CRESCENT BIOPHARMA, INC. (CBIO) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent of 5.10% for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-13.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost · last filed 2025-02-13
- CRESCENT BIOPHARMA, INC. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2024 was 5.10%.
- CRESCENT BIOPHARMA, INC. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2023 was -2.30%.
- CRESCENT BIOPHARMA, INC. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2018 was 0.10%, a 85.71% decline from fiscal 2017.
- CRESCENT BIOPHARMA, INC. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2017 was 0.70%, a 0.00% change from fiscal 2016.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent 12 month |
|---|---|
| 2024-12-31 | 5.10% 10-K · filed 2025-02-13 |
| 2023-12-31 | -2.30% 10-K · filed 2025-02-13 |
| 2018-12-31 | 0.10% 10-K · filed 2021-03-02 |
| 2017-12-31 | 0.70% 10-K · filed 2020-02-28 |
| 2016-12-31 | 0.70% 10-K · filed 2019-03-06 |
| 2015-12-31 | 1.80% 10-K · filed 2018-03-06 |
| 2014-12-31 | 1.30% 10-K · filed 2017-03-01 |
| 2013-12-31 | 4.40% 10-K · filed 2016-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |